Semaglutide Reduces BMI Category for Adolescents With Obesity
Improvement of one or more BMI category seen for majority of participants receiving semaglutide.
Diagnosis & Disease Information
Glycemic Control Improved With Exercise in the Afternoon
Afternoon exercise group had greatest reduction in HbA1c at year 1 among adults with overweight or obesity and type 2 diabetes.
FDA Issues Warning About Compounded Versions of Wegovy, Ozempic
The FDA does not review compounded drugs for safety, effectiveness, or quality; compounded medications are not FDA-approved
Using Nutrition as Medicine for Mental Health
Expert discusses identifying and managing nutrient deficiencies or eating habits that can contribute to mental health conditions including depression and anxiety
Specific Postoperative Complications Increased for Patients With Obesity
Odds of infection, venous thromboembolism, renal complications increased for patients with overweight, obesity.
Certain Wegovy Strengths Expected to Be in Short Supply
Wegovy is a glucagon-like peptide-1 receptor agonist.
Substantial Weight Loss Reductions Observed With Tirzepatide in T2D Patients
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Higher Dietary Choline, Betaine Intake May Benefit Individuals With Obesity
Researchers analyzed the relationship between dietary choline and betaine intake and serum lipids, blood pressure, and glycemic markers among individuals with obesity.
Coming Soon: Personalized Medicine for Weight Loss
Dr Zhaoping Li discusses 2 ongoing studies investigating the use of precision nutrition for personalized weight loss plans.
Obesity Drivers Differ by Sex
The findings contribute to the understanding of neurological factors driving the sex-specific pathophysiology of obesity.
- Loading...
Loading...
Next post in Obesity Information Center
Loading... 
Loading...